Kampschreur Linda M, Oosterheert Jan Jelrik, Hoepelman Andy I M, Lestrade Peter J, Renders Nicole H M, Elsman Peter, Wever Peter C
Division of Medicine, Department of Internal Medicine and Infectious Diseases, University Medical Centre Utrecht, Utrecht, the Netherlands.
Clin Vaccine Immunol. 2012 Aug;19(8):1165-9. doi: 10.1128/CVI.00185-12. Epub 2012 Jun 13.
Chronic Q fever develops in 1 to 5% of patients infected with Coxiella burnetii. The risk for chronic Q fever endocarditis has been estimated to be ≈ 39% in case of preexisting valvulopathy and is potentially even higher for valvular prostheses. Since 2007, The Netherlands has faced the largest Q fever outbreak ever reported, allowing a more precise risk estimate of chronic Q fever in high-risk groups. Patients with a history of cardiac valve surgery were selected for microbiological screening through a cardiology outpatient clinic in the area where Q fever is epidemic. Blood samples were analyzed for phase I and II IgG against C. burnetii, and if titers were above a defined cutoff level, C. burnetii PCR was performed. Chronic Q fever was considered proven if C. burnetii PCR was positive and probable if the phase I IgG titer was ≥ 1:1,024. Among 568 patients, the seroprevalence of C. burnetii antibodies (IgG titer greater than or equal to 1:32) was 20.4% (n = 116). Proven or probable chronic Q fever was identified among 7.8% of seropositive patients (n = 9). Valve characteristics did not influence the risk for chronic Q fever. Patients with chronic Q fever were significantly older than patients with past Q fever. In conclusion, screening of high-risk groups is a proper instrument for early detection of chronic Q fever cases. The estimated prevalence of chronic Q fever is 7.8% among seropositive patients with a history of cardiac valve surgery, which is substantially higher than that in nonselected populations but lower than that previously reported. Older age seems to increase vulnerability to chronic Q fever in this population.
1%至5%感染伯氏考克斯体的患者会发展为慢性Q热。据估计,既往存在瓣膜病的患者发生慢性Q热心内膜炎的风险约为39%,而对于人工瓣膜患者,该风险可能更高。自2007年以来,荷兰面临着有史以来报告的最大规模Q热疫情,这使得对高危人群中慢性Q热的风险估计更为精确。在Q热流行地区,通过心脏病门诊对有心脏瓣膜手术史的患者进行微生物筛查。分析血样中针对伯氏考克斯体的I期和II期IgG,如果滴度高于规定的临界值水平,则进行伯氏考克斯体PCR检测。如果伯氏考克斯体PCR检测呈阳性,则认为慢性Q热确诊;如果I期IgG滴度≥1:1024,则认为可能为慢性Q热。在568例患者中,伯氏考克斯体抗体的血清阳性率(IgG滴度大于或等于1:32)为20.4%(n = 116)。在7.8%的血清阳性患者(n = 9)中发现了确诊或可能的慢性Q热。瓣膜特征不影响慢性Q热的风险。慢性Q热患者的年龄显著大于既往感染过Q热的患者。总之,对高危人群进行筛查是早期发现慢性Q热病例的合适手段。在有心脏瓣膜手术史的血清阳性患者中,慢性Q热的估计患病率为7.8%,这大大高于未选择人群,但低于先前报告的患病率。在该人群中,年龄较大似乎会增加患慢性Q热的易感性。